OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NURS58

Hydreight Technologies Inc

Advanced Medical Equipment & TechnologyVerified

Hydreight Technologies Inc has a debt-to-equity ratio of 0.42, indicating a relatively conservative capital structure with equity financing playing a larger role than debt. The company reported negative operating cash flow of CAD -1.87 million and capital expenditures of CAD -1.52 million, suggesting ongoing investment in operations and infrastructure. Despite these outflows, the company maintains a medium liquidity risk rating, with total liabilities of CAD 14.05 million and total equity of CAD 19.70 million. Profitability metrics for Hydreight Technologies Inc are not explicitly provided, but the negative operating cash flow and capital expenditures suggest the company is in a growth or development phase. The company's financials do not include key profitability metrics such as EBITDA or net income, which would be necessary to compare against industry benchmarks. The company's revenue is reported at CAD 35.39 million, but no segment or geographic breakdown is provided in the available data. This lack of detail makes it difficult to assess the concentration of revenue across different product lines or regions. Looking ahead, the company's growth trajectory is not clearly defined in the available data. Analysts have assigned a mean price target of CAD 9.75, with a median of CAD 9.75 and a range from CAD 9.50 to CAD 10.00. The mean recommendation is 2.00, indicating a "buy" rating, with two buy recommendations and no strong buy or hold ratings. The company faces a medium liquidity risk, with negative net cash after subtracting total debt. While dilution risk is currently rated as low, the company's capital structure and ongoing cash outflows could change this if additional financing is required. No recent events such as filings or transcripts are provided in the available data to further assess the company's strategic direction or operational developments.

30-day price · NURS+1.44 (+56.0%)
Low$2.44High$4.52Close$4.01As of14 May, 00:00 UTC
Profile
CompanyHydreight Technologies Inc
TickerNURS.V
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Hydreight Technologies Inc develops and sells advanced medical equipment, primarily focused on hydration and infusion technologies for healthcare applications.

Classification. The company is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Hydreight Technologies Inc has a debt-to-equity ratio of 0.42, indicating a relatively conservative capital structure with equity financing playing a larger role than debt. The company reported negative operating cash flow of CAD -1.87 million and capital expenditures of CAD -1.52 million, suggesting ongoing investment in operations and infrastructure. Despite these outflows, the company maintains a medium liquidity risk rating, with total liabilities of CAD 14.05 million and total equity of CAD 19.70 million. Profitability metrics for Hydreight Technologies Inc are not explicitly provided, but the negative operating cash flow and capital expenditures suggest the company is in a growth or development phase. The company's financials do not include key profitability metrics such as EBITDA or net income, which would be necessary to compare against industry benchmarks. The company's revenue is reported at CAD 35.39 million, but no segment or geographic breakdown is provided in the available data. This lack of detail makes it difficult to assess the concentration of revenue across different product lines or regions. Looking ahead, the company's growth trajectory is not clearly defined in the available data. Analysts have assigned a mean price target of CAD 9.75, with a median of CAD 9.75 and a range from CAD 9.50 to CAD 10.00. The mean recommendation is 2.00, indicating a "buy" rating, with two buy recommendations and no strong buy or hold ratings. The company faces a medium liquidity risk, with negative net cash after subtracting total debt. While dilution risk is currently rated as low, the company's capital structure and ongoing cash outflows could change this if additional financing is required. No recent events such as filings or transcripts are provided in the available data to further assess the company's strategic direction or operational developments.
Key takeaways
  • Hydreight Technologies Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.42.
  • The company is investing in operations and infrastructure, as indicated by negative operating cash flow and capital expenditures.
  • Analysts have assigned a "buy" rating to the stock, with a mean price target of CAD 9.75.
  • The company's growth trajectory and profitability metrics are not clearly defined in the available data.
  • The company faces medium liquidity risk, with negative net cash after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue$35.4M
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow-$1.9M
CapEx-$1.5M
Free cash flow
Total assets
Total liabilities$14.1M
Total equity$19.7M
Cash & equivalents
Long-term debt$8.4M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash-$8.4M
Current ratio
Debt/Equity0.4
ROA
ROE
Cash conversion
CapEx/Revenue-4.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricNURSActivity
Op margin-16.5% medp25 -174.5% · p75 8.8%
Net margin-16.5% medp25 -172.4% · p75 8.4%
Gross margin47.4% medp25 34.2% · p75 65.3%
CapEx / revenue-4.3%-5.4% medp25 -12.5% · p75 -2.2%above median
Debt / equity42.0%4.3% medp25 0.0% · p75 28.0%top quartile
Observations
IR observations
Mean price target9.75 CAD
Median price target9.75 CAD
High price target10.00 CAD
Low price target9.50 CAD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.30 CAD
Last actual EPS0.02 CAD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-13 01:01 UTC#de696381
Market quoteclose CAD 4.20 · shares 0.05B diluted
no public URL
2026-05-13 01:02 UTC#a6d8293d
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 19:26 UTCJob: 88ea34b2